Anixa Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Anixa Biosciences Inc (ANIX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Anixa Biosciences Inc vs Its Competitors
- Scale: Anixa Biosciences Inc ranks #274 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Anixa Biosciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Anixa Biosciences Inc | - | - | - | Yes |
| Competitors combined (44) | ||||
| High-Confidence Competitors (2) | - | |||
| Similar-Size Competitors (8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ANIX Stock Performance relative to its Competitors
ANIX Stock Performance relative to High-Confidence Competitors
ANIX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 4 | Immunovant Inc | 282.9% | Outperformed |
| 5 | Zymeworks Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Anixa Biosciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Anixa Biosciences Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Anixa Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Anixa Biosciences Inc |
104.60 | - |
 Akari Therapeutics Plc |
846,737.51 | - |
 Abbvie Inc |
520,773.08 | 66,014.00 |
 Madrigal Pharmaceuticals Inc |
13,113.46 | 1,427.94 |
 Nuvalent Inc |
9,751.98 | 4.23 |
 Rhythm Pharmaceuticals Inc |
7,867.80 | 280.75 |
| SUBTOTAL | 1,434,923.23 | 70,710.99 |
Sign in to see all competitors of Anixa Biosciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Anixa Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Anixa Biosciences Inc's Competitors Named by the Company
Competitive relationships identified from Anixa Biosciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AWH | Company report | 85% |
| Aspira Women s Health inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Anixa Biosciences Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Anixa Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Anixa Biosciences Inc .
Anixa Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Anixa Biosciences Inc | 105 | - | -2,617,000 |
| Akari Therapeutics Plc | 846,738 | - | -4,674,667 |
| Abbvie Inc | 520,773 | 1,158,140 | 181,509 |
| Madrigal Pharmaceuticals Inc | 13,113 | 1,560,590 | -169,905 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Rhythm Pharmaceuticals Inc | 7,868 | 678,135 | -476,599 |
| PEERS TOTAL | 1,434,819 | 1,115,632 | 120,959 |
Sign in to see all peers for Anixa Biosciences Inc .
Anixa Biosciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Iovance Biotherapeutics inc | US 98.66 % |
| Hutchmed china Limited | CN 74.28 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.73 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Anixa Biosciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Anixa Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Anixa Biosciences Inc ranks #274 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 983, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,267,410 | 23.79 % |
| 2 | Johnson and Johnson | 688,169 | 12.92 % |
| 3 | Abbvie Inc | 519,284 | 9.75 % |
| 4 | Merck and Co Inc | 364,892 | 6.85 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 274 | Anixa Biosciences Inc | 105 | 0.00 % |
Market cap and industry share for the rest of Anixa Biosciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Anixa Biosciences Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 269 | Lexaria Bioscience Corp | 117 | 352.88 % |
| 270 | Semnur Pharmaceuticals Inc | 115 | -94.44 % |
| 271 | Nkarta Inc | 113 | -22.45 % |
| 272 | Satellos Bioscience Inc | 110 | 24.34 % |
| 273 | Pyxis Oncology Inc | 1,234 | 12.3% |
| 274 | Anixa Biosciences Inc | 105 | -26.49 % |
| 275 | Rani Therapeutics Holdings Inc | 1,234 | 12.3% |
| 276 | Tuhura Biosciences Inc | 1,234 | 12.3% |
| 277 | Medicus Pharma Ltd | 1,234 | 12.3% |
| 278 | Nervgen Pharma Corp | 1,234 | 12.3% |
| 279 | Neonc Technologies Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Anixa Biosciences Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Anixa Biosciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | - | 15.4x | - |
| P/B | 6.8x | 4.2x | +2.6x |
| Return on Equity | -0.73 % | industry aggregate | -17.08 % |
| Return on Invested Capital | - | -9.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Anixa Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -157.35 % | -92.68 % | -57.48 % | -21.14 % | -21.61 % | -25.23 % | -35.32 % | -39.27 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Anixa Biosciences Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Anixa Biosciences Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.3% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Anixa Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 983 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Anixa Biosciences Inc's dedicated Suppliers and Customers pages, not here.
Anixa Biosciences Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Anixa Biosciences Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Anixa Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 17.1 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (45.20 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Anixa Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Anixa Biosciences Inc | 2.48 | 8.55 | - |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Rhythm Pharmaceuticals Inc | 1.01 | 3.60 | 0.94 |
Sign in to see all peers for Anixa Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Anixa Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Anixa Biosciences Inc | Q2 2026 | - | - |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Rhythm Pharmaceuticals Inc | Q3 2026 | +79.6 % | - |
| PEERS TOTAL | +14.7 % | - |
Sign in to see all peers for Anixa Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Anixa Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Anixa Biosciences Inc | Q2 2026 | - | - |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Rhythm Pharmaceuticals Inc | Q3 2026 | +121.2 % | -98.8 % |
Sign in to see all peers for Anixa Biosciences Inc .
Anixa Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Anixa Biosciences Inc | - | - | - |
| Akari Therapeutics Plc | - | - | - |
| Abbvie Inc | 7.48% | 12.87% | - |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Nuvalent Inc | - | - | - |
| Rhythm Pharmaceuticals Inc | - | - | - |
Sign in to see all peers for Anixa Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Anixa Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Anixa Biosciences Inc | - | - |
| Akari Therapeutics Plc | - | - |
| Abbvie Inc | 50.58 | 7.89 |
| Madrigal Pharmaceuticals Inc | - | 9.18 |
| Nuvalent Inc | - | 2,303.80 |
| Rhythm Pharmaceuticals Inc | - | 28.02 |
| PEERS AVERAGE | 187.42 | 20.29 |
Sign in to see all peers for Anixa Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.